Amylyx (AMLX) Pharmaceuticals announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by Amylyx. Amylyx intends to use the net proceeds from this offering, together with existing cash, cash equivalents and marketable securities, for Avexitide commercial readiness, research and development, and working capital and other general corporate purposes. Leerink Partners and Guggenheim Securities are acting as lead bookrunning managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx price target raised to $14 from $10 at BofA
- Amylyx Pharmaceuticals Halts ORION Program for AMX0035
- Amylyx to discontinue ORION program of AMX0035
- Amylyx Pharmaceuticals Advances Phase 3 Study on Avexitide for Post-Bariatric Hypoglycemia
- Amylyx Pharmaceuticals’ Promising Earnings Call Highlights